Literature DB >> 20372879

Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens.

Stephanie R Ebner1, Mitchell F Roitman, David N Potter, Anna B Rachlin, Elena H Chartoff.   

Abstract

RATIONALE: Kappa opioid receptors (KORs) have been implicated in depressive-like states associated with chronic administration of drugs of abuse and stress. Although KOR agonists decrease dopamine in the nucleus accumbens (NAc), KOR modulation of phasic dopamine release in the core and shell subregions of the NAc-which have distinct roles in reward processing-remains poorly understood.
OBJECTIVES: Studies were designed to examine whether the time course of effects of KOR activation on phasic dopamine release in the NAc core or shell are similar to effects on motivated behavior.
METHODS: The effect of systemic administration of the KOR agonist salvinorin A (salvA)-at a dose (2.0 mg/kg) previously determined to have depressive-like effects-was measured on electrically evoked phasic dopamine release in the NAc core or shell of awake and behaving rats using fast scan cyclic voltammetry. In parallel, the effects of salvA on intracranial self-stimulation (ICSS) and sucrose-reinforced responding were assessed. For comparison, a threshold dose of salvA (0.25 mg/kg) was also tested.
RESULTS: The active, but not threshold, dose of salvA significantly decreased phasic dopamine release without affecting dopamine reuptake in the NAc core and shell. SalvA increased ICSS thresholds and significantly lowered breakpoint on the progressive ratio schedule, indicating a decrease in motivation. The time course of the KOR-mediated decrease in dopamine in the core was qualitatively similar to the effects on motivated behavior.
CONCLUSIONS: These data suggest that the effects of KOR activation on motivation are due, in part, to inhibition of phasic dopamine signaling in the NAc core.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372879      PMCID: PMC2894632          DOI: 10.1007/s00213-010-1836-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  76 in total

1.  Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments.

Authors:  V Bassareo; G Di Chiara
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

Review 2.  The structural basis for mapping behavior onto the ventral striatum and its subdivisions.

Authors:  Gloria E Meredith; Brian A Baldo; Matthew E Andrezjewski; Ann E Kelley
Journal:  Brain Struct Funct       Date:  2008-02-07       Impact factor: 3.270

3.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

4.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

5.  Nucleus accumbens dopamine depletions and time-constrained progressive ratio performance: effects of different ratio requirements.

Authors:  S Hamill; J T Trevitt; K L Nowend; B B Carlson; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  1999-09       Impact factor: 3.533

6.  Postcocaine anhedonia. An animal model of cocaine withdrawal.

Authors:  A Markou; G F Koob
Journal:  Neuropsychopharmacology       Date:  1991-01       Impact factor: 7.853

Review 7.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

8.  Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum.

Authors:  B A Sorg; P W Kalivas
Journal:  Brain Res       Date:  1991-09-13       Impact factor: 3.252

9.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

10.  Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food.

Authors:  R A Wise; J Spindler; H deWit; G J Gerberg
Journal:  Science       Date:  1978-07-21       Impact factor: 47.728

View more
  76 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Effects of extended-release injectable naltrexone on self-injurious behavior in rhesus macaques (Macaca mulatta).

Authors:  Doty J Kempf; Kate C Baker; Margaret H Gilbert; James L Blanchard; Reginald L Dean; Daniel R Deaver; Rudolf P Bohm
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

3.  Voluntary ethanol intake predicts κ-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques.

Authors:  Cody A Siciliano; Erin S Calipari; Verginia C Cuzon Carlson; Christa M Helms; David M Lovinger; Kathleen A Grant; Sara R Jones
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

4.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

5.  Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.

Authors:  Elena Chartoff; Allison Sawyer; Anna Rachlin; Dave Potter; Andrea Pliakas; William A Carlezon
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Modulation of serotonin transporter function by kappa-opioid receptor ligands.

Authors:  Santhanalakshmi Sundaramurthy; Balasubramaniam Annamalai; Devadoss J Samuvel; Toni S Shippenberg; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Neuropharmacology       Date:  2016-10-12       Impact factor: 5.250

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

10.  Switch from excitatory to inhibitory actions of ethanol on dopamine levels after chronic exposure: Role of kappa opioid receptors.

Authors:  Anushree N Karkhanis; Kimberly N Huggins; Jamie H Rose; Sara R Jones
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.